Abstract:The gut-liver axis covers the bidirectional communication between the gut and the liver, and thus includes signals from liver-to-gut (e.g., bile acids, immunoglobulins) and from gut-to-liver (e.g., nutrients, microbiota-derived products, and recirculating bile acids). In a healthy individual, liver homeostasis is tightly controlled by the mostly tolerogenic liver resident macrophages, the Kupffer cells, capturing the gut-derived antigens from the blood circulation. However, disturbances of the gut-liver axis have been associated to the progression of varying chronic liver diseases, such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and primary sclerosing cholangitis. Notably, changes of the gut microbiome, or intestinal dysbiosis, combined with increased intestinal permeability, leads to the translocation of gut-derived bacteria or their metabolites into the portal vein. In the context of concomitant or subsequent liver inflammation, the liver is then infiltrated by responsive immune cells (e.g., monocytes, neutrophils, lymphoid, or dendritic cells), and microbiota-derived products may provoke or exacerbate innate immune responses, hence perpetuating liver inflammation and fibrosis, and potentiating the risks of developing cirrhosis. Similarly, food derived antigens, bile acids, danger-, and pathogen-associated molecular patterns are able to reshape the liver immune microenvironment. Immune cell intracellular signaling components, such as inflammasome activation, toll-like receptor or nucleotide-binding oligomerization domain-like receptors signaling, are potent targets of interest for the modulation of the immune response. This review describes the current understanding of the cellular landscape and molecular pathways involved in the gut-liver axis and implicated in chronic liver disease progression. We also provide an overview of innovative therapeutic approaches and current clinical trials aiming at targeting the gut-liver axis for the treatment of patients with chronic liver and/or intestinal diseases.

Role of bile acids in liver diseases mediated by the gut microbiome

Bile Acids and Microbiota: Multifaceted and Versatile Regulators of the Liver–Gut Axis

Role of Bile Acids in Dysbiosis and Treatment of Nonalcoholic Fatty Liver Disease

The influence of bile acid, microbiota and their interaction on inflammatory bowel disease and the related progress in clinical application

Molecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases

Crosstalk between Gut Microbiota and Bile Acids in Cholestatic Liver Disease

Bile acid metabolism and signaling, the microbiota, and metabolic disease

Bile acids and their receptors in regulation of gut health and diseases

The Role of Gut Microbiota in Some Liver Diseases: From an Immunological Perspective

Bile Acids: A Communication Channel in the Gut-Brain Axis

Interactive Relationships Between Intestinal Flora and Bile Acids.

Role of Intestinal Microbes in Chronic Liver Diseases

Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics

Bile acid–microbiota crosstalk in gastrointestinal inflammation and carcinogenesis

Exploring the role of a novel postbiotic bile acid: Interplay with gut microbiota, modulation of the farnesoid X receptor, and prospects for clinical translation

Role of bile acids in inflammatory liver diseases

The Gut-liver Axis in Immune Remodeling: New insight into Liver Diseases

Role of gut microbiota via the gut-liver-brain axis in digestive diseases

[The gut-liver axis: how the gut promotes liver disease]

The regulatory role of bile acid microbiota in the progression of liver cirrhosis

Emerging roles of bile acids in mucosal immunity and inflammation